Dr. Dixon is CSO/Head R&D of Mithra Pharmaceutical SA (EBR: MITRA). In his 27 year career in the pharmaceutical industry, he has worked in a range of R&D management positions at AstraZeneca plc and in C-level management positions in several biotech companies: COO, F2G Ltd; CSO, Entomed SA; CSO, Galapagos NV (AMS:GLPG);  CSO, Addex Therapeutics SA (SWX:ADXN);  COO, Sensorion SA (EPA:ALSEN), CSO, Onxeo SA, (EPA:ONXEO) and CEO, Neem Biotech Ltd.  Dr Dixon has played leadership roles in the successful regulatory clearance of three compounds: Meropenem® (AstraZeneca), Belinostat® (Onxeo) and Nextellis®/Drovelis® (Mithra); 12 proof-of-concept studies; two successful IPOs (Galapagos & Sensorion) and 10 clinical stage licensing deals. He is a non-executive director and chairman of HepaRegeniX GmbH, a non-executive director of Alligator Bioscience AB as well as an advisor to several venture capital organisations and their portfolio companies.